T cell Bim levels reflect responses to anti-PD-1 cancer therapy.

@article{Dronca2016TCB,
  title={T cell Bim levels reflect responses to anti-PD-1 cancer therapy.},
  author={Roxana Stefania Dronca and Xin Liu and Susan M. Harrington and Lingling Chen and Siyu Cao and Lisa A. Kottschade and Robert R McWilliams and Matthew S. Block and Wendy Kay Nevala and Michael Allen Thompson and Aaron S Mansfield and Sean Park and Svetomir N. Markovic and Haidong Dong},
  journal={JCI insight},
  year={2016},
  volume={1 6}
}
Immune checkpoint therapy with PD-1 blockade has emerged as an effective therapy for many advanced cancers; however, only a small fraction of patients achieve durable responses. To date, there is no validated blood-based means of predicting the response to PD-1 blockade. We report that Bim is a downstream signaling molecule of the PD-1 pathway, and its detection in T cells is significantly associated with expression of PD-1 and effector T cell markers. High levels of Bim in circulating tumor… CONTINUE READING
Highly Cited
This paper has 29 citations. REVIEW CITATIONS
Recent Discussions
This paper has been referenced on Twitter 16 times over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.
15 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

Similar Papers

Loading similar papers…